The Novavax Covid-19 vaccine could be cleared by regulators for use in multiple countries, including the U.S., in the coming months, the vaccine-maker’s CEO said Monday.

The vaccine could be in high demand. Novavax’s vaccine is protein based, using an alternative technology to the more widespread mRNA vaccines. Skeptics leery of the mRNA technology may be inclined to get the Novavax version, Erck said, which also has been seen to present fewer adverse side effects than other vaccines.